Dignitana Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Dignitana wird ein jährliches Gewinn- und Umsatzwachstum von 113.8% bzw. 19.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 118.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 91.4% betragen.

Wichtige Informationen

113.8%

Wachstumsrate der Gewinne

118.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	36.6%
Wachstumsrate der Einnahmen	19.3%
Zukünftige Eigenkapitalrendite	91.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	23 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

The Dignitana AB (publ.) (STO:DIGN) Share Price Is Up 123% And Shareholders Are Boasting About It

Dec 10

Gewinn- und Umsatzwachstumsprognosen

OM:DIGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	133	20	31	36	1
12/31/2025	101	-3	N/A	3	1
12/31/2024	89	-25	-16	-11	1
9/30/2024	88	-23	-6	-1	N/A
6/30/2024	86	-25	-10	-5	N/A
3/31/2024	86	-18	-10	-4	N/A
12/31/2023	86	-17	-10	-6	N/A
9/30/2023	85	-24	-18	-13	N/A
6/30/2023	82	-24	-20	-15	N/A
3/31/2023	79	-20	-23	-19	N/A
12/31/2022	73	-22	-21	-18	N/A
9/30/2022	69	-22	-26	-23	N/A
6/30/2022	64	-33	-35	-29	N/A
3/31/2022	60	-42	-45	-36	N/A
12/31/2021	57	-43	-54	-44	N/A
9/30/2021	54	-52	-51	-38	N/A
6/30/2021	51	-48	-47	-33	N/A
3/31/2021	48	-48	-35	-20	N/A
12/31/2020	47	-53	-42	-21	N/A
9/30/2020	43	-47	-50	-26	N/A
6/30/2020	42	-48	-54	-31	N/A
3/31/2020	43	-45	-57	-31	N/A
12/31/2019	41	-38	-48	-27	N/A
9/30/2019	40	-28	-73	-55	N/A
6/30/2019	40	-24	-64	-47	N/A
3/31/2019	37	-22	-25	-12	N/A
12/31/2018	34	-26	-32	-21	N/A
9/30/2018	31	-34	2	20	N/A
6/30/2018	26	-38	N/A	12	N/A
3/31/2018	23	-43	N/A	-34	N/A
12/31/2017	23	-43	N/A	-33	N/A
9/30/2017	21	-41	N/A	-45	N/A
6/30/2017	19	-38	N/A	-46	N/A
3/31/2017	14	-34	N/A	-37	N/A
12/31/2016	9	-32	N/A	-31	N/A
9/30/2016	17	-59	N/A	-76	N/A
6/30/2016	15	-56	N/A	-69	N/A
3/31/2016	15	-53	N/A	-68	N/A
12/31/2015	17	-50	N/A	-64	N/A
9/30/2015	14	-12	N/A	-12	N/A
6/30/2015	17	-11	N/A	-3	N/A
3/31/2015	23	-9	N/A	-2	N/A
12/31/2014	21	-11	N/A	-3	N/A
9/30/2014	16	-15	N/A	1	N/A
6/30/2014	13	-16	N/A	-13	N/A
3/31/2014	8	-18	N/A	-17	N/A
12/31/2013	11	-17	N/A	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DIGN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.2%).

Ertrag vs. Markt: DIGN wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: DIGN wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: DIGNDie Einnahmen des Unternehmens (19.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-0.04% pro Jahr).

Hohe Wachstumseinnahmen: DIGNDie Einnahmen des Unternehmens (19.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DIGNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (91.4%).

Dignitana Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.052 loss in 3Q 2023)

New minor risk - Financial position

Second quarter 2024 earnings released: kr0.14 loss per share (vs kr0.066 loss in 2Q 2023)

Dignitana AB (publ) to Report Q1, 2025 Results on May 22, 2025

New major risk - Market cap size

Dignitana AB (publ) Announces the Resignation of William Cronin as Deputy Chairman of the Board, Effective 24 June 2024

New minor risk - Shareholder dilution

Dignitana AB (Publ) Approves the Election of Fredrik Lindgren and Hope S. Rugo as Board Members

Dignitana AB (Publ) Announces Chief Executive Officer Changes , Effective May 2, 2024

Dignitana AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 19.128698 million.

Dignicap Delta Study Underway in Brindisi, Italy

Dignitana AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 19.128698 million.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dignitana Announces DigniCap Delta Receives Market Approval in Japan

Dignitana Announces Preliminary Results of DigniCap Delta Study Demonstrates 79% Efficacy

Third quarter 2023 earnings released: kr0.052 loss per share (vs kr0.056 loss in 3Q 2022)

Dignitana AB (publ) to Report Fiscal Year 2023 Final Results on May 02, 2024

Dignitana AB (publ), Annual General Meeting, May 23, 2024

Dignitana (STO:DIGN) Is Carrying A Fair Bit Of Debt

Dignitana AB Announces Palmetto GBA Approves First Local Coverage Determination for Scalp Cooling Therapy

Dignitana AB Long-Term Study Demonstrates Safety and Efficacy of Scalp Cooling to Reduce Chemo Hair Loss

Second quarter 2023 earnings released: kr0.066 loss per share (vs kr0.004 loss in 2Q 2022)

New minor risk - Share price stability

We Think Dignitana (STO:DIGN) Has A Fair Chunk Of Debt

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Dignitana AB (publ) to Report Fiscal Year 2022 Final Results on May 04, 2023

Third quarter 2022 earnings released: kr0.056 loss per share (vs kr0.21 loss in 3Q 2021)

Dignitana AB Appoints Nomination Committee

Dignitana AB (publ) Hires Johan Johansson to Head Operations, Research and Development

Less than half of directors are independent

Dignitana AB (publ) Launches DigniCap Direct Partner Portal

Second quarter 2022 earnings released: kr0.004 loss per share (vs kr0.15 loss in 2Q 2021)

We Think Dignitana (STO:DIGN) Has A Fair Chunk Of Debt

Dignitana AB (publ) to Report Q1, 2023 Results on May 25, 2023

Now 26% undervalued after recent price drop

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Dignitana AB (publ) Appoints Ulf Jönsson as Chief Financial Officer

Should You Investigate Dignitana AB (publ) (STO:DIGN) At kr6.04?

Now 24% undervalued after recent price drop

Less than half of directors are independent

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Dignitana AB (publ.) (STO:DIGN) Is Carrying A Fair Bit Of Debt

Full year 2021 earnings: EPS and revenues miss analyst expectations

Dignitana AB (publ.) Appoints Alf Christensson as Interim CFO, Effective March 1, 2022

Dignitana Appoints Catarina Mård Löwenadler as CEO

Third quarter 2021 earnings released: kr0.21 loss per share (vs kr0.18 loss in 3Q 2020)

Dignitana AB (publ.) (STO:DIGN) Has Debt But No Earnings; Should You Worry?

Second quarter 2021 earnings released: kr0.15 loss per share (vs kr0.17 loss in 2Q 2020)

Dignitana AB Launches New Initiatives to Support Reimbursement and Market Access

Independent Director has left the company

Independent Director has left the company

First quarter 2021 earnings released: kr0.12 loss per share (vs kr0.23 loss in 1Q 2020)

New 90-day low: kr7.84

Full year 2020 earnings released: kr0.96 loss per share (vs kr0.76 loss in FY 2019)

Dignitana AB (publ.) (STO:DIGN) Has Debt But No Earnings; Should You Worry?

New 90-day high: kr8.94

Dignitana AB Announces Highly Recognized Mammazentrum Hamburg Is Upgrading Their Existing Scalp Cooling Program to the Next Generation Dignicap Delta System

The Dignitana AB (publ.) (STO:DIGN) Share Price Is Up 123% And Shareholders Are Boasting About It

GenesisCare selects Dignitana as Preferred Scalp Cooling Provider for its Rapidly Expanding Australia Medical Oncology Centres

Dignitana AB (publ.) to Report Q3, 2021 Results on Nov 18, 2021

Cancer Leader City of Hope Selects Dignitana AB (Publ.) for Community Network in California

Dignitana AB Announces Agreement with ION Solutions

New 90-day high - kr8.06

Earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken